TheraRadar
← Back
Data updated: Jun 28, 2026

PHOENIX LABS NY

Generics

PHOENIX LABS NY is a generic drug manufacturer focused on Respiratory, Dermatology.

1974
Since
5
Drugs
-
Trials
0
New Drugs (2yr)

PHOENIX LABS NY's Key Drugs

PHOENIX LABS NY's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

PHOENIX LABS NY's Recent FDA Approvals

New NDA/BLA approvals for PHOENIX LABS NY over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

PHOENIX LABS NY's Therapeutic Areas

PHOENIX LABS NY's approved drugs and pipeline span 2 therapeutic areas, led by Respiratory and Dermatology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Respiratory 50%
1 drugs
Dermatology 50%
1 drugs

PHOENIX LABS NY's Top Competitors

PHOENIX LABS NY's closest competitors by therapeutic-area and drug-target overlap include Bayer, APOTHECON, and PHARMACIA AND UPJOHN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

PHOENIX LABS NY Pipeline Snapshot

Active clinical trials for PHOENIX LABS NY across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Respiratory pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling